Cargando…

Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study

BACKGROUND: Diabetes mellitus-related cardiomyopathy (DMCMP), defined as left ventricular (LV) dysfunction caused by hyperglycemia in the absence of coronary artery disease, leads to heart failure (HF). Previous studies have shown that treatment with sodium-glucose co-transporter 2 inhibitor (SGLT2i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oka, Satoshi, Kai, Takahiko, Hoshino, Katsuomi, Watanabe, Kazunori, Nakamura, Jun, Abe, Makoto, Watanabe, Akinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086321/ https://www.ncbi.nlm.nih.gov/pubmed/33926386 http://dx.doi.org/10.1186/s12872-021-02024-3

Ejemplares similares

Tracheobronchial Obstruction Due to Blood Clots in Acute Pulmonary Embolism with Cardiac Arrest Managed with Extracorporeal Membrane Oxygenation
por: Watanabe, Kazunori, et al.
Publicado: (2021)

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
por: Levine, Matthew J.
Publicado: (2017)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
por: Trang, Nguyen Ngoc, et al.
Publicado: (2021)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study
por: Althobaiti, Fahad M., et al.
Publicado: (2022)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019)

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
por: Anderson, John E., et al.
Publicado: (2016)

Fournier’s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus
por: Khokhar, Farzam, et al.
Publicado: (2022)

Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function
por: Wang, Jinwu, et al.
Publicado: (2022)

Alternative Splicing Regulator RBM20 and Cardiomyopathy
por: Watanabe, Takeshi, et al.
Publicado: (2018)

Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
por: Schwaiger, Elisabeth, et al.
Publicado: (2019)

New CTO-Specific IVUS: AnteOwl Success in Previously Failed CTO Case Treated With Navifocus IVUS
por: Suzuki, Satoshi, et al.
Publicado: (2020)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Kinduryte Schorling, Ona, et al.
Publicado: (2020)

Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
por: Chauhan, Sukhjinder, et al.
Publicado: (2023)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
por: Mozawa, Kosuke, et al.
Publicado: (2021)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Wire Cutting Method Using Rotational Atherectomy for Stretched Spring Wire During Coronary Intervention
por: Tanaka, Kota, et al.
Publicado: (2021)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
por: Nakamura, Kazufumi, et al.
Publicado: (2022)

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
por: Neeland, Ian J, et al.
Publicado: (2016)

Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials
por: Zhang, Yun-Jing, et al.
Publicado: (2018)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
por: Lunder, Mojca, et al.
Publicado: (2018)

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Hsu, Jung-Chi, et al.
Publicado: (2019)

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
por: Jürgens, Mikkel, et al.
Publicado: (2021)

Possibility of AnteOwl IVUS–based antegrade dissection and reentry using the tip detection method for CTO-PCI
por: Okamura, Atsunori, et al.
Publicado: (2022)

A case and video presentation using rotational ETOSS of intentional route tracing by angiography-based 3D wiring in CTO-PCI
por: Okamura, Atsunori, et al.
Publicado: (2022)

Calcified Nodules in the Superficial Femoral Artery Confirmed by Intravascular Ultrasound, Angioscopy, and Histology
por: Tanaka, Kota, et al.
Publicado: (2020)

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
por: McGill, Janet B.
Publicado: (2014)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2013)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
por: Cherney, David ZI, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bv3q3013c54umg6vsvorklt3t5